CIK 1766721
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 13 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | BBIO | BridgeBio Pharma, Inc. | Health Care | 79.35% |
| 2 | SNDX | Syndax Pharmaceuticals Inc | Health Care | 6.46% |
| 3 | GLUE | Monte Rosa Therapeutics, Inc. | Health Care | 5.37% |
| 4 | BCAX | Bicara Therapeutics Inc. | Health Care | 2.38% |
| 5 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Health Care | 1.91% |
| 6 | CMPS | COMPASS Pathways plc | Health Care | 1.66% |
| 7 | SRRK | Scholar Rock Holding Corp | Health Care | 0.80% |
| 8 | BMEA | Biomea Fusion, Inc. | Health Care | 0.66% |
| 9 | EPRX | EUPRAXIA PHARMACEUTICALS INC. | Health Care | 0.49% |
| 10 | URGN | UroGen Pharma Ltd. | Health Care | 0.41% |
13/13 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/13 names) · unclassified 100.0%: BBIO, SNDX, GLUE, BCAX, BBOT, CMPS, SRRK, BMEA, EPRX, URGN +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | BBIOBRIDGEBIO PHARMA INC | 5,089,611 | $378M | 79.4% | HOLD |
| 2 | SNDXSYNDAX PHARMACEUTICALS INC | 1,316,806 | $31M | 6.5% | HOLD |
| 3 | GLUEMONTE ROSA THERAPEUTICS INC | 1,555,664 | $26M | 5.4% | ADD 6% |
| 4 | BCAXBICARA THERAPEUTICS INC | 568,919 | $11M | 2.4% | HOLD |
| 5 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 1,018,018 | $9M | 1.9% | ADD 80% |
| 6 | CMPSCOMPASS PATHWAYS PLC | 1,432,336 | $8M | 1.7% | ADD 20% |
| 7 | SRRKSCHOLAR ROCK HLDG CORP | 77,031 | $4M | 0.8% | HOLD |
| 8 | BMEABIOMEA FUSION INC | 2,048,757 | $3M | 0.7% | HOLD |
| 9 | EPRXEupraxia Pharmaceuticals Inc | 325,000 | $2M | 0.5% | NEW |
| 10 | URGNUROGEN PHARMA LTD | 108,000 | $2M | 0.4% | HOLD |
| 11 | ACRSACLARIS THERAPEUTICS INC | 434,455 | $2M | 0.3% | HOLD |
| 12 | MRKRMARKER THERAPEUTICS INC | 325,370 | $422,981 | 0.1% | HOLD |
| 13 | OKURONKURE THERAPEUTICS INC | 88,607 | $366,833 | 0.1% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| BBIOBRIDGEBIO PHARMA INC | 6.1M | 6.1M | 6.1M | 6.1M | 5.1M | 5.1M | $378M |
| SNDXSYNDAX PHARMACEUTICALS INC | 1.0M | 1.0M | 1.3M | 1.3M | 1.3M | 1.3M | $31M |
| GLUEMONTE ROSA THERAPEUTICS INC | 1.5M | 1.5M | 1.5M | 1.5M | 1.5M | 1.6M | $26M |
| BCAXBICARA THERAPEUTICS INC | 569K | 569K | 569K | 569K | 569K | 569K | $11M |
| BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | — | — | — | 565K | 565K | 1.0M | $9M |
| CMPSCOMPASS PATHWAYS PLC | 965K | 1.2M | 1.2M | 1.2M | 1.2M | 1.4M | $8M |
| SRRKSCHOLAR ROCK HLDG CORP | — | — | — | 77K | 77K | 77K | $4M |
| BMEABIOMEA FUSION INC | 799K | 799K | 2.0M | 2.0M | 2.0M | 2.0M | $3M |
| EPRXEupraxia Pharmaceuticals Inc | — | — | — | — | — | 325K | $2M |
| URGNUROGEN PHARMA LTD | — | — | — | — | 108K | 108K | $2M |
| ACRSACLARIS THERAPEUTICS INC | 434K | 434K | 434K | 434K | 434K | 434K | $2M |
| MRKRMARKER THERAPEUTICS INC | 325K | 325K | 325K | 325K | 325K | 325K | $422,981 |
| OKURONKURE THERAPEUTICS INC | 89K | 89K | 89K | 89K | 89K | 89K | $366,833 |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
